Prostadiag®
An accurate tissue-based test
to predict non-evolutive localized prostate cancer (LPCa)
Workflow
- Use of next generation sequencing (NGS) technology for gene expression analysis
- A sensitive quantification of RNA biomarkers of interest
- A software for an accurate rendering of results
Clinical validation in 2021
Training set: preliminary results
Patent
EP18305060, 2018: Molecular signature and use thereof for the identification of indolent prostate cancer.
Publication
Kamoun A, Cancel-Tassin G, Formont g, elarouci N, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology. 2018 August 1814-1821.
https://doi.org/10.1093/annonc/mdy224
